Source: CureToday articles
Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ advanced/metastatic NSCLC.
Recent Content
- Hepatitis B and C virus infection and risk of multiple myeloma: a systematic review and meta-analysis
- Recombinant Human Hyaluronidase-Facilitated SCIg Sustains Clinical Remission in Idiopathic Inflammatory Myositis
- Researchers Identify Sex-Based Differences In Diet and Metabolism
- Addressing Complications from ADT Therapy to Treat Prostate Cancer
- Study: LYR-210 Shows Promise in Chronic Rhinosinusitis with Nasal Polyps
- ASCO 2025: Fixed-Duration Treatment Emerges as Future of Multiple Myeloma Management
- New or Persistent Acid Reflux May Signal Esophageal Cancer Risk
- Neoadjuvant Osimertinib With or Without Chemotherapy Improves Response in Resectable EGFRm NSCLC
- Continuing Novel Therapeutic Research Presents New Options in Lung Cancer
- Fixed-Duration Ibrutinib Plus Venetoclax Shows Long-Term Efficacy in First-Line CLL/SLL Treatment